Evidence map›Paper›PMID 29651149›Full record

ArticleScientific reports2018

Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.

Josephine B Walton, Malcolm Farquharson, Susan Mason, Jennifer Port, Bjorn Kruspig, Suzanne Dowson, David Stevenson, Daniel Murphy, Martin Matzuk, Jaeyeon Kim and 3 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Josephine B WaltonInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Malcolm FarquharsonInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Susan MasonCancer Research UK Beatson Institute, Glasgow, UK.
Jennifer PortCancer Research UK Beatson Institute, Glasgow, UK.
Bjorn KruspigCancer Research UK Beatson Institute, Glasgow, UK.
Suzanne DowsonInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0003-2511-1965
David StevensonCancer Research UK Beatson Institute, Glasgow, UK.
Daniel MurphyInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0002-5538-5468
Martin MatzukDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
Jaeyeon KimDepartments of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Seth CoffeltCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-2257-2862
Karen BlythCancer Research UK Beatson Institute, Glasgow, UK.
Iain A McNeishInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK. i.mcneish@imperial.ac.uk.ORCID http://orcid.org/0000-0002-9387-7586
Cancer Research UK Scotland Institute · GBUniversity of Glasgow · GBBaylor College of Medicine · USIndiana University School of Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.

Identifiers

PMID29651149
PMCPMC5897571
OpenAlexW2797235468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.